| Followers | 129 |
| Posts | 2150 |
| Boards Moderated | 1 |
| Alias Born | 12/27/2007 |
Tuesday, February 04, 2020 9:48:52 AM
FDA DECISION ON FEB.20--- GREAT buying opp
BXRX =MC $79 M -Cash $20 M- Shares Out 9 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
BXRX =MC $79 M -Cash $20 M- Shares Out 9 M / FDA DECISION ON FEB.20 for Non-Opioid Pain Drug / UNKNOWN Gem = 500%+ Upside
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
